SCHEMBL4383070

SCHEMBL4383070

Cc1noc(C)c1S(=O)(=O)N1CCC(=NOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.47
▸ HTT P42858 1/20 0.46
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ SCN9A Q15858 1/20 0.44
▸ CHRM4 P08173 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ MAPK1 P28482 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ CCNT1 O60563 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM5 P08912 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4381279 0.79 PKM (0.49) ALDH1A1MEN1KMT2ALMNA
SCHEMBL4377766 0.77 NR3C1 (0.40) ALDH1A1HTTMEN1KMT2ALMNA
SCHEMBL4392624 0.76 GAA (0.40) ALDH1A1MEN1KMT2ALMNAMAPK1
SCHEMBL4382795 0.76 THRB (0.43) ALDH1A1MEN1KMT2ASMN1; SMN2TP53
SCHEMBL8212403 0.75 MEN1 (0.33) ALDH1A1MEN1KMT2ALMNASMN1; SMN2
SCHEMBL4390159 0.74 MEN1 (0.49) ALDH1A1HTTMEN1KMT2ASCN9A
SCHEMBL4391478 0.74 PKM (0.52) ALDH1A1HTTMEN1KMT2ALMNA
SCHEMBL4382549 0.74 TP53 (0.46) LMNATSHRTP53
SCHEMBL4382575 0.74 KMT2A (0.52) ALDH1A1HTTMEN1KMT2ALMNA
SCHEMBL4385272 0.74 PKM (0.54) ALDH1A1KMT2ALMNATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 ALDH1A1 2105/4885HTT 4042/4885MEN1 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback